Ipratop250 mcg/ml

Ipratop is a short-acting anticholinergic (antimuscarinic) bronchodilator used in respiratory disease. Its uses are classified below by strength of evidence:

• Established/FDA-approved use — Chronic Obstructive Pulmonary Disease (COPD): Maintenance treatment of bronchospasm associated with chronic bronchitis and emphysema, delivered by metered-dose inhaler or nebulizer solution.
• Established/FDA-approved use — Rhinorrhea: Nasal spray formulations of Ipratop (0.03% and 0.06%) are indicated for symptomatic relief of rhinorrhea associated with allergic and non-allergic perennial rhinitis, and with the common cold, respectively.
• Guideline-supported adjunct use — Acute asthma exacerbation: Nebulized Ipratop is recommended by asthma management guidelines as an add-on to inhaled short-acting beta-agonists (SABA) in the emergency treatment of moderate-to-severe acute asthma attacks; it is used in combination with a SABA, not as monotherapy, and is not intended as a stand-alone rescue medication.
• Combination therapy: Ipratop is frequently formulated together with albuterol (salbutamol) for combined bronchodilation in COPD and acute bronchospasm, taking advantage of the two drugs' complementary mechanisms.

Ipratop is not indicated as the sole agent for rapid relief of acute bronchospasm, since its onset of action is slower than that of short-acting beta-agonists.

Each formulation contains Ipratropium Bromide as the active ingredient. Common marketed strengths and forms include:

• Metered-dose inhaler (aerosol): 17–20 mcg of Ipratropium Bromide per actuation.
• Nebulizer solution: 0.02% (equivalent to 250 mcg/mL or 500 mcg per 2.5 mL unit-dose vial).
• Nasal spray: 0.03% and 0.06% strengths.
• Combination inhaler/nebules with albuterol (salbutamol), containing Ipratropium Bromide plus a short-acting beta-agonist.

Inactive ingredients vary by manufacturer and may include propellants (in aerosol forms), sodium chloride, and preservatives such as benzalkonium chloride (in some nasal/nebulizer formulations).

Ipratop is a synthetic quaternary ammonium anticholinergic (antimuscarinic) compound, structurally related to atropine, used as a bronchodilator in obstructive airway disease and, in nasal spray form, for control of rhinorrhea.

Because it carries a permanent positive charge (quaternary ammonium structure), Ipratop is poorly absorbed across biological membranes, including the respiratory and gastrointestinal mucosa. This limits its action largely to the site of administration and minimizes systemic anticholinergic effects compared with atropine.

Ipratop is delivered by inhalation (metered-dose inhaler or nebulizer) for airway disease, or intranasally for rhinorrhea, and is available both as a single-ingredient product and in fixed-dose combination with albuterol (salbutamol).

Anticholinergic (antimuscarinic) bronchodilator; Ipratop belongs to the short-acting muscarinic antagonist (SAMA) class of respiratory drugs.

Mechanism of Action

Ipratropium Bromide competitively and reversibly blocks the action of acetylcholine at muscarinic (M1, M2, and M3) receptors on bronchial smooth muscle and submucosal glands. By antagonizing vagally-mediated cholinergic tone, it prevents the increase in intracellular cyclic guanosine monophosphate (cGMP) caused by acetylcholine binding, resulting in relaxation of bronchial smooth muscle (bronchodilation) and reduced mucus gland secretion. In the nasal mucosa, blockade of muscarinic receptors on submucosal glands reduces watery nasal secretions (rhinorrhea) without significantly affecting nasal congestion.

Pharmacokinetics

Following inhalation, only a small fraction (roughly 10–30%, depending on the device) of the dose reaches the lungs; most is swallowed. Because Ipratropium Bromide is a quaternary ammonium compound, systemic absorption from both the lung and the gastrointestinal tract is minimal (absolute bioavailability well under 10%), which limits systemic anticholinergic side effects. Onset of bronchodilation begins within 15 minutes, peaks at 1–2 hours, and effects last approximately 4–6 hours. Ipratropium Bromide undergoes partial hepatic metabolism to inactive ester-hydrolysis products, and the absorbed fraction is eliminated mainly via renal excretion.

Ipratop inhalation products are for oral inhalation (mouth) only; the nasal spray is for intranasal use only — the two forms are not interchangeable. Patients should be shown correct inhaler, nebulizer, or nasal-spray technique by a healthcare professional, since inadequate technique reduces drug delivery to the airway or nasal mucosa. Rinse the mouth after inhaled use is not typically required for Ipratop alone (unlike inhaled corticosteroids), but any accidental contact with the eyes should be avoided and eyes rinsed promptly with water if it occurs.

Clinically significant, well-verified interactions with Ipratop include:

• Other anticholinergic (antimuscarinic) agents (e.g., tiotropium, other long-acting muscarinic antagonists, certain antihistamines, tricyclic antidepressants): concurrent use may produce additive anticholinergic effects such as dry mouth, urinary retention, constipation, and blurred vision. Concurrent use of Ipratop with another inhaled anticholinergic bronchodilator is generally not recommended.
• Short-acting and long-acting beta-agonists and methylxanthines (e.g., theophylline): these are commonly co-administered with Ipratop for additive bronchodilator effect; no clinically important pharmacokinetic interaction is established, but combined use should be monitored for additive cardiovascular stimulant effects when used with beta-agonists.

Because systemic absorption of Ipratop is minimal, clinically significant interactions with systemically-acting drugs (e.g., via cytochrome P450 metabolism) have not been well established.

The most commonly reported adverse effects of Ipratop are related to its local anticholinergic action:

• Very common/common: dry mouth, headache, cough, and throat irritation.
• Common: nausea, dizziness, dyspepsia (indigestion), and blurred vision (especially with accidental eye contact).
• Uncommon: palpitations, tachycardia, urinary retention or difficulty voiding (particularly in patients with pre-existing bladder outlet obstruction), and constipation.
• Rare but serious: paradoxical bronchospasm (a sudden worsening of wheeze/breathlessness immediately after use — treatment should be discontinued and alternative therapy sought if this occurs), acute angle-closure glaucoma or worsening of narrow-angle glaucoma from ocular exposure, and immediate hypersensitivity reactions such as angioedema, urticaria, or anaphylaxis (see Contraindications).

Pregnancy: There are no adequate and well-controlled studies of Ipratop in pregnant women. Because systemic absorption is minimal, systemic fetal exposure is expected to be low, but Ipratop should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use in pregnancy.

Lactation: It is not known whether Ipratop is excreted in human breast milk. Given its low systemic bioavailability, systemic exposure of a breastfed infant is expected to be minimal, but caution is advised and a physician or lactation specialist should be consulted before use while breastfeeding.

• Ocular effects: Avoid spraying or nebulizing Ipratop into the eyes; direct ocular contact (more likely with a nebulizer mask than a mouthpiece) can precipitate or worsen narrow-angle glaucoma, and can cause eye pain, blurred vision, mydriasis (pupil dilation), and halos around lights. Patients with pre-existing narrow-angle glaucoma should use Ipratop with caution and be counseled to protect their eyes during nebulization.
• Urinary retention: Use with caution in patients with bladder outlet obstruction or prostatic hyperplasia, as anticholinergic effects may worsen urinary retention.
• Paradoxical bronchospasm: As with other inhaled bronchodilators, Ipratop can rarely cause immediate paradoxical bronchospasm. If this occurs, the medication should be discontinued immediately and alternative therapy instituted.
• Hypersensitivity to soy/peanut: Some Ipratop inhaler formulations contain soy lecithin as an excipient; these should be avoided in patients with known hypersensitivity to soybean or peanut, because of possible allergic cross-reactivity.
• Not a rescue medication: Ipratop has a slower onset of bronchodilation than short-acting beta-agonists and is not intended for the initial rapid relief of acute, severe bronchospasm as a sole agent; it should be used according to the prescribed regimen, in combination with a fast-acting bronchodilator when rescue therapy is needed.

Because systemic absorption of Ipratop is minimal after inhaled or intranasal use, significant systemic toxicity from accidental overdose is unlikely; however, exaggerated anticholinergic effects such as dry mouth, blurred vision, tachycardia, urinary retention, and constipation could theoretically occur with excessive use. If overdose is suspected, or if the patient experiences severe or unusual symptoms, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic, as there is no specific antidote for Ipratop.

Store at room temperature (below 30°C), away from light, excessive heat, and moisture. Do not puncture, break, or burn the inhaler canister, and avoid exposing it to freezing temperatures or direct sunlight. Keep out of reach of children.

• Renal impairment: No specific dose adjustment is well established, given minimal systemic absorption of Ipratop; use with routine clinical caution.
• Hepatic impairment: No specific dose adjustment is well established; use with routine clinical caution.
• Elderly: No age-related dose adjustment is generally required, but elderly patients may be more susceptible to anticholinergic effects such as urinary retention and glaucoma exacerbation (see Precautions and Warnings).
• Pediatric: See Pediatric Uses for age-specific approved indications and dosing.

For COPD, Ipratop is generally used as long-term, regular maintenance therapy for as long as the physician determines it is needed to control symptoms; it is not intended to be stopped and started intermittently for symptom relief alone. For acute asthma exacerbations, Ipratop is used short-term, only for the duration of the acute episode, as an adjunct to a short-acting beta-agonist, and is typically discontinued once the exacerbation resolves and the patient reverts to their usual maintenance regimen. For rhinorrhea, the nasal spray is generally used only for as long as symptoms persist, with the 0.06% common-cold formulation limited to a maximum of 4 days of use. Any change in duration of Ipratop therapy should be directed by the prescribing physician.

Ipratropium Bromide belongs to the anticholinergic (antimuscarinic) bronchodilator class, also referred to as short-acting muscarinic antagonists (SAMA); related classes include long-acting muscarinic antagonists (e.g., tiotropium) and beta-2 agonist bronchodilators, with which Ipratropium Bromide is often combined.

Ipratropium Bromide works by competitively blocking muscarinic acetylcholine receptors (M1, M2, M3) on airway smooth muscle and submucosal glands, thereby inhibiting the bronchoconstrictor and secretory effects mediated by the vagus nerve. This antagonism reduces the resting bronchomotor tone that is driven by cholinergic (parasympathetic) activity, producing bronchodilation and decreased mucus secretion. Because Ipratropium Bromide is a quaternary ammonium compound with poor lipid solubility, its action is largely confined to the site of deposition (airway or nasal mucosa), with minimal systemic anticholinergic effect.

B

Use of Ipratop in children is indication- and formulation-specific:

• Nasal spray 0.03% (rhinorrhea, allergic/perennial rhinitis): approved for use in children 6 years of age and older, at the same dosing frequency as adults.
• Nasal spray 0.06% (rhinorrhea with the common cold): approved for use in children 5 years of age and older, for a maximum of 4 days.
• Inhalation aerosol (MDI) for COPD: COPD is uncommon in children, and safety and efficacy of the inhaler for this indication have not been established in the pediatric population.
• Nebulizer solution in acute asthma (off-label/guideline-directed use): nebulized Ipratop is commonly used as an adjunct to short-acting beta-agonists in children with moderate-to-severe acute asthma exacerbations under direct medical supervision (e.g., in the emergency department), even though it is not formally approved as a stand-alone pediatric indication; safety and efficacy for routine outpatient/home use in children have not been established, and use in infants and young children should be guided by a pediatrician.